BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1617 related articles for article (PubMed ID: 29942092)

  • 21. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
    Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
    Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
    Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
    Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
    Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonality, Antigen Recognition, and Suppression of CD8
    Hammerl D; Massink MPG; Smid M; van Deurzen CHM; Meijers-Heijboer HEJ; Waisfisz Q; Debets R; Martens JWM
    Clin Cancer Res; 2020 Jan; 26(2):505-517. PubMed ID: 31649042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [CD8 and FOXP3 expression in stromal tumor-infiltrating lymphocytes of triple-negative breast carcinomas: a clinicopathologic study].
    Pan BJ; Ping GQ; Zhang WM; Wang C; Li HX; Zhang ZH
    Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):540-4. PubMed ID: 27510779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer.
    Ma X; Zhao X; Yan W; Yang J; Zhao X; Zhang H; Hui Y; Zhang S
    Cancer Biomark; 2018 Feb; 21(3):639-650. PubMed ID: 29286921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-cell RNA sequencing of human breast tumour-infiltrating immune cells reveals a γδ T-cell subtype associated with good clinical outcome.
    Boufea K; González-Huici V; Lindberg M; Symeonides S; Oikonomidou O; Batada NN
    Life Sci Alliance; 2021 Jan; 4(1):. PubMed ID: 33268347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implication of CD69
    Kim HD; Jeong S; Park S; Lee YJ; Ju YS; Kim D; Song GW; Lee JH; Kim SY; Shin J; Shin EC; Hwang S; Yoo C; Park SH
    Liver Int; 2021 Apr; 41(4):764-776. PubMed ID: 33548061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer.
    Lee HJ; Kim A; Song IH; Park IA; Yu JH; Ahn JH; Gong G
    Pathol Int; 2016 Apr; 66(4):202-9. PubMed ID: 26922571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
    Carbognin L; Pilotto S; Nortilli R; Brunelli M; Nottegar A; Sperduti I; Giannarelli D; Bria E; Tortora G
    Oncologist; 2016 Mar; 21(3):283-91. PubMed ID: 26865589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
    Chung YR; Kim HJ; Jang MH; Park SY
    Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4-1BB-Enhanced Expansion of CD8
    Harao M; Forget MA; Roszik J; Gao H; Babiera GV; Krishnamurthy S; Chacon JA; Li S; Mittendorf EA; DeSnyder SM; Rockwood KF; Bernatchez C; Ueno NT; Radvanyi LG; Vence L; Haymaker C; Reuben JM
    Cancer Immunol Res; 2017 Jun; 5(6):439-445. PubMed ID: 28473315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
    Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
    Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
    Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
    Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased Stromal Infiltrating Lymphocytes Are Associated with the Risk of Disease Progression in Mesenchymal Circulating Tumor Cell-Positive Primary Breast Cancer Patients.
    Smolkova B; Cierna Z; Kalavska K; Miklikova S; Plava J; Minarik G; Sedlackova T; Cholujova D; Gronesova P; Cihova M; Majerova K; Karaba M; Benca J; Pindak D; Mardiak J; Mego M
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.